Synergistic effect of Si-hydroxyapatite coating and VEGF adsorption on Ti6Al4V-ELI scaffolds for bone regeneration in an osteoporotic bone environment. by Izquierdo-Barba, Isabel et al.
Accepted Manuscript
Full length article
Synergistic effect of Si-hydroxyapatite coating and VEGF adsorption on
Ti6Al4V-ELI scaffolds for bone regeneration in an osteoporotic bone environ-
ment
I. Izquierdo-Barba, L. Santos-Ruiz, J. Becerra, M.J. Feito, D. Fernández-Villa,
M.C. Serrano, I. Díaz-Güemes, B. Fernández-Tomé, S. Enciso, F.M. Sánchez-




To appear in: Acta Biomaterialia
Received Date: 23 July 2018
Revised Date: 7 November 2018
Accepted Date: 12 November 2018
Please cite this article as: Izquierdo-Barba, I., Santos-Ruiz, L., Becerra, J., Feito, M.J., Fernández-Villa, D., Serrano,
M.C., Díaz-Güemes, I., Fernández-Tomé, B., Enciso, S., Sánchez-Margallo, F.M., Monopoli, D., Afonso, H.,
Portolés, M.T., Arcos, D., Vallet-Regí, M., Synergistic effect of Si-hydroxyapatite coating and VEGF adsorption
on Ti6Al4V-ELI scaffolds for bone regeneration in an osteoporotic bone environment, Acta Biomaterialia (2018),
doi: https://doi.org/10.1016/j.actbio.2018.11.017
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process




Synergistic effect of Si-hydroxyapatite coating and VEGF 
adsorption on Ti6Al4V-ELI scaffolds for bone regeneration in 
an osteoporotic bone environment   
I. Izquierdo-Barba1,2,, L. Santos-Ruiz2,3,4,, J. Becerra,2,3,4 M. J. Feito5, D. Fernández-
Villa5, M. C. Serrano6, I. Díaz-Güemes7, B. Fernández-Tomé7, S. Enciso7, F. M. 
Sánchez-Margallo7, D. Monopoli8, H. Afonso8, M. T. Portolés5*, D. Arcos1,2* M. Vallet-
Regí1,2* 
1. Dpto. de Química en Ciencias Farmacéuticas, Facultad de Farmacia, Universidad 
Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre 
i+12, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain 
2. CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN), Spain 
3. Dpto. de Biología Celular, Genética y Fisiología, Instituto de Investigación Biomédica 
de Málaga (IBIMA), Universidad de Málaga, Spain 
4. Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), c/ Severo Ochoa 
35, 29590 Campanillas-Málaga, Spain 
5. Dpto. de Bioquímica y Biología Molecular, Facultad de Ciencias Químicas, Universidad 
Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San 
Carlos (IdISSC), Ciudad Universitaria, 28040 Madrid, Spain. 
6. Instituto de Ciencia de Materiales de Madrid (ICMM), Consejo Superior de 
Investigaciones Científicas (CSIC), 28049 Madrid, Spain 
7. Centro de Cirugía de Mínima Invasión Jesús Usón, Cáceres, Spain 
8. Dpto. Ingeniería Biomédica. Instituto Tecnológico de Canarias, Spain 
* Corresponding authors: portoles@quim.ucm.es (M.T. Portolés), arcosd@ucm.es (D. 
Arcos) and vallet@ucm.es (M. Vallet-Regí) 





The osteogenic and angiogenic responses to metal macroporous scaffolds coated with 
silicon substituted hydroxyapatite (SiHA) and decorated with vascular endothelial 
growth factor (VEGF) have been evaluated in vitro and in vivo. Ti6Al4V-ELI scaffolds 
were prepared by electron beam melting and subsequently coated with 
Ca10(PO4)5.6(SiO4)0.4(OH)1.6 following a dip coating method. In vitro studies 
demonstrated that SiHA stimulates the proliferation of MC3T3-E1 pre-osteoblastic 
cells, whereas the adsorption of VEGF stimulates the proliferation of EC2 mature 
endothelial cells. In vivo studies were carried out in an osteoporotic sheep model, 
evidencing that only the simultaneous presence of both components led to a significant 
increase of new tissue formation in osteoporotic bone. 
 
STATEMENT OF SIGNIFICANCE 
Reconstruction of bones after severe trauma or tumors extirpation is one of the most 
challenging tasks in the field of orthopedic surgery. This scenario is even more complicated in 
the case of osteoporotic patients, since their bone regeneration capability is decreased. In this 
work we present a porous implant that promotes bone regeneration even in osteoporotic 
bone. By coating the implant with an osteogenic bioceramics such as silicon substituted 
hydroxyapatite and subsequent adsorption of vascular endothelial growth factor, these 
implants stimulate the bone ingrowth when they are implanted in osteoporotic sheep 
 
 






Osteoporosis is the most prevalent skeletal disorder in humans older than 50, involving 
a significant impact on fracture prevalence in the elderly [1,2]. This disease entails a 
decrease in both bone density and quality, leading to fractures that frequently  involves 
disability and even death. [3] Certainly, fractures are the main clinical consequences of 
osteoporosis, which are often severely comminuted, especially in trabecular bone areas 
[4]. But this scenario is even more complex when osteoporotic patients undergo severe 
trauma entailing the loss of bone mass. The mesenchymal stem cells of osteoporotic 
bone have less capacity to differentiate into osteoblasts, together with a decreased 
angiogenic capacity at the defect site [5]. In these cases, biomaterials used for bone 
grafting and augmentation must also cope with delayed bone healing and impair 
osseointegration [6-9]. In this sense, strategies such as association of antiosteoporotics 
drugs to bone grafts have been previously considered [10-12]. 
An alternative to the current substitutive strategies in the treatment of bone 
defects is the concept of functionalized metallic macroporous scaffolds [13]. These 
scaffolds must facilitate the osteogenesis and new blood vessels formation within their 
macroporous structure, while exhibiting optimal mechanical behavior. Both aspects are 
mandatory for the regeneration of bone defects, particularly in osteoporotic bones. 
The surface functionalization of these metal structures with a highly bioactive 
bioceramic has emerged as a very promising alternative [14,15]. Moreover, these 
bioceramics can facilitate fixation of growth factors involved in the osteogenic 
processes [16-19]. Silicon substituted hydroxyapatite (SiHA) has become one of the 
most attractive bioceramics for use as bone substitute material [20-23] for spinal, 
orthopedic, periodontal, oral and craniomaxillofacial applications. SiHA presents 




early stages of bone formation [24]. The favorable effects of Si substitution in HA have 
been explained by considering passive and active mechanisms as material solubility 
increase, topographical changes, grain size reduction, surface charge modifications and 
ionic release of Si and Ca, which directly act on bone cells [25-29].  
Vascular endothelial growth factor (VEGF) is involved in angiogenesis and 
vascular homeostasis [30] and plays an essential role for regulating angiogenesis, 
endothelial cell function and signaling [31]. The angiogenic process accompanies bone 
regeneration acting as limiting factor for the healing process [32]. More specifically 
VEGF regulates angiogenesis, maturation of osteoblasts, ossification, and bone 
turnover. Thus, osteogenesis and vascularization are coupled during bone development 
and growth [33-36].  
In this study, we evaluated the osteogenic and angiogenic responses to bone 
implants coated with Si-HA and VEGF for bone defects in an osteoporotic sheep model. 
Macroporous scaffolds of Ti6Al4V-ELI fabricated by electron beam melting were used 
as supporting structures and substrates to be coated with SiHA and incubated with 
VEGF to carry out the adsorption of this growth factor on their surface with a minimal 
desorption [19]. Ti6Al4V-ELI implants provide strong scaffolding to the bone while 
exhibiting porosities higher than 50% in volume. Consequently, it would be highly 
desirable if they exhibited osteogenic capabilities to enhance bone ingrowth within the 
macroporous structure.  
We hypothesized that the presence of immobilized VEGF together with Si-HA 
would result in a better angiogenic response and stimulation of new bone formation 
from both, inner site and peripheral area of the bone defect. To test this hypothesis, we 
evaluated the in vitro response of endothelial and pre-osteoblastic cells to the above 




cavitary defect of osteoporotic sheep, then evaluating the new bone and blood vessels 
formation.  
2. Materials and Methods 
2.1 Scaffolds preparation and coating 
Macroporous structures of Ti6Al4V ELI were prepared by electron beam melting. 
Cylinders of 1 cm in diameter and 1 cm in height were designed containing a 3D 
interconnected macroporosity (supporting information Fig S1). The cylindrical 
structures exhibit pores of 2 mm in diameter and wall thickness around 700 – 800 m, 
thus resulting in highly porous structures with large free volume to allow bone 
ingrowth. The Ti6Al4V – ELI scaffolds so manufactured were coated with Si-HA of 
nominal composition Ca10(PO4)5.6(SiO4)0.4(OH)1.6, following a dip-coating process. 
Aqueous sols were prepared by hydrolyzing 2.58 mL and 0.136 mL of triethyl 
phosphite P(OCH2CH3)3 (TIP) and tetraethyl orthosilicate Si(OCH2CH3)4 (TEOS), 
respectively, in 1.04 mL of H2O. The solution was stirred at 200 rpm for 24 hours to 
hydrolyze both alkoxides. This solution was subsequently poured to a second solution 
of 1.21 g of a non-ionic surfactant Pluronic F127 (EO106PO70EO106) in 13.1 g of ethanol. 
After 30 min under stirring, 6.25 mL of 4 M Ca(NO3)2·4H2O solution were added, thus 
keeping Ca/P+Si molar ratio to 1.67 as corresponds to Ca10(PO4)5.6(SiO4)0.4(OH)1.6. The 
mixed sol was stirred for 15 min and subsequently aged at 60ºC for 24 hours. After that, 
ethanol was added until doubling the volume. The sol was deposited by the dip-coating 
method at room temperature with a withdrawal rate of 1,000 m/s, dried in air for 1 
hour at room temperature and subsequently annealed at 550ºC for 10 minutes under air 
atmosphere to remove the surfactant and to produce the SiHA phase. With the aim of 




2.2 Immobilization of VEGF on Ti6Al4V structures 
Non-coated Ti6Al4V (Ti) and SiHA-coated Ti6Al4V scaffolds (Ti@SiHA) were 
introduced into 24 well culture plates (CULTEK S. L. U., Madrid, Spain) and sterilized 
under ultraviolet light during 1 hour for each side in a sterile environment. Adsorption 
and immobilization of Vascular Endothelial Growth Factor (VEGF) on scaffold 
surfaces was carried out through non-covalent binding by incubation of each scaffold 
with 5 g/mL of VEGF-A (VEGF-121, 583204, Biolegend, San Diego, CA, USA) in 
phosphate buffered saline (PBS, Sigma-Aldrich, St Louis, MO, USA) at 4 ºC for 
various times. Cylinders of 1 cm in diameter and 0.5 cm in height were used for the in 
vitro studies and coated with 500 L of VEGF solution. For the in vivo studies, 
cylinders of 1 cm in diameter and 1 cm in height were coated with 1 ml of VEGF 
solution.  The samples were stored at 4ºC for 24 h before the in vitro and in vivo studies. 
After 0, 0.5 and 24 hours of incubation, the concentration of desorbed VEGF in the 
supernatants was analyzed by using an enzyme linked immunosorbent assay (ELISA, 
Cloud-Clone Corp, USA). The adsorbed VEGF amount was indirectly calculated as the 
difference between the VEGF levels at the initial time and after each incubation time. 
The standard curve was carried out according to the manufacturer’s instructions. The 
sensitivity of these assays was less than 6.1 pg/mL. In agreement with previous studies 
[19], a minimal desorption of immobilized VEGF was observed. 
Four groups of samples were used in these in vitro and in vivo studies: 
- Ti6Al4V-ELI scaffolds (Ti) 
- Ti6Al4V-ELI scaffolds with adsorbed VEGF (Ti-VEGF) 
- Ti6Al4V-ELI scaffolds coated with Si-HA (Ti@SiHA) 





2.3 Physico-chemical characterization 
The scaffolds were characterized by X-ray diffraction (XRD), scanning electron 
microscopy (SEM) and Fourier transform infrared spectroscopy (FTIR). XRD patterns 
were collected directly from the coated scaffolds using the grazing incidence technique 
with a Philips X’Pert diffractometer (KCu radiation, =1,5418 Å). Scanning electron 
microscopy was carried out with a JEOL 6400 Microscope-Oxford Pentafet super ATW 
microscope equipped with a LINK “Pentafet” detector for EDX analyses. Fourier 
transform infrared (FTIR) spectroscopy was carried out with a Nicolet Magma IR 550 
spectrometer. The samples were prepared by scratching the coatings deposited on the 
Ti6Al4V scaffolds. The spectra were collected using the attenuated total reflectance 
(ATR) technique with a Golden Gate ATR device. 
2.4  Culture of endothelial cells on Ti6Al4V structures 
Mature endothelial cells EC2 obtained from porcine peripheral blood (see supporting 
information) were seeded on the scaffolds at a density of 3x105 cells/mL in EGM-2 
(Lonza, Walkersville, MD, USA). EGM-2 without VEGF was used for the culture of 
EC2 on these scaffolds in order to evaluate the effects of the VEGF immobilized on 
scaffold surface. All the samples were incubated under 5% CO2 atmosphere at 37 ºC for 
3 days. 
2.5 Culture of MC3T3-E1 pre-osteoblasts on Ti6Al4V structures 
Murine pre-osteoblastic MC3T3-E1 cells (subclone 4, CRL-2593, ATCC, Manassas, 
VA, USA) were seeded on scaffolds at a density of 6x105 cells/mL in Dulbecco's 




supplemented with 10% fetal bovine serum (FBS, Gibco, BRL), 1 mM L-glutamine 
(BioWhittaker Europe, Belgium), penicillin (200 μg/mL, BioWhittaker Europe, 
Belgium), and streptomycin (200 μg/mL, BioWhittaker Europe, Belgium). All the 
samples were incubated under 5% CO2 atmosphere at 37 ºC for 3 days. 
2.6 Cell proliferation assay: CCK-8 
Proliferation of both endothelial cells (EC2) and MC3T3 pre-osteoblasts was measured 
using the Cell Counting Kit-8 (CCK-8) protocol (Sigma-Aldrich, St Louis, MO, USA). 
After incubation for 3-4 hours under 5% CO2 atmosphere at 37 ºC, three samples of 100 
L of each well were collected into 96 well culture plates (Nunc Brand, Rochester, NY, 
USA) to have triplicates of each initial sample and absorbance was measured at 450 nm. 
2.7 Scanning electron microscopy (SEM) studies 
After CCK-8 protocol, the samples were used for SEM analysis because WST-8 does 
not damage living cells. Cells attached to the scaffolds were fixed by incubation with 
2.5% glutaraldehyde (Merck KGaA, Darmstadt, Germany) for 1 h at 4 ºC. Then, 
successive dehydration steps were carried out by slow water replacement, using a series 
of ethanol solutions (30%, 50%, 70%, 80% and 90%) for 10 min and final dehydration 
in absolute ethanol for 10 min, allowing the samples to dry at room temperature. 
Afterwards, the pieces were mounted on stubs and coated in vacuum with gold–
palladium. Samples were then examined with a JEOL JSM-6400 scanning electron 
microscope (Centro Nacional de Microscopía Electrónica, Madrid, Spain). 
2.8 In vivo studies in osteoporotic sheep model 
This study was approved by our Institutional Ethical Committee following the 




and of the Council of September 22, 2010, on the protection of animals used for 
scientific purposes). 
Induction of osteoporotic model 
Six 4-year-old female Merino sheep (mean preoperative weight of 43.78 ± 5.9 Kg) were 
included in the study, and all of them were operated on to place with the four implants 
described above at distinct locations. To reproduce similar conditions as osteoporosis in 
humans, six months before the implantation all sheep underwent, under sterile 
conditions and general anaesthesia induced by propofol (4 mg/kg) and maintained by 
isoflurane (1.5%), a laparoscopic bilateral ovariectomy (see supporting information for 
further details). At the same time, a low-calcium diet (0.5%) and corticosteroids 
administration (500 mg methylprednisolone via intramuscular injection every 3 weeks) 
were implemented until the end of the study.  
Implantation surgical procedure 
Six months after the ovariectomy, the biomaterials were blindly implanted in the sheep 
under aseptic conditions and the same anaesthetic protocol previously described. Six 
cylindrical defects (10x13mm) were created in each sheep by drilling the cancellous 
bone of the proximal tibia epiphysis, medial epicondyle of the femur and greater 
tuberosity of the humerus, under continuous irrigation with cold sterile saline, as 
described by Nuss et al. [37]. The sample size for each type of scaffold was n = 6. Two 
defects in each sheep were left empty as control. Once the biomaterials were randomly 
implanted, the muscular and subcutaneous tissue was approximated with absorbable 
monofilament suture and the skin with absorbable braided suture (Figure S2 in 
supporting information). Postoperative analgesia was maintained with buprenorphine 




was administered for 7 days as prophylactic antibiotherapy. The health condition of all 
animals was checked daily along the whole study by an accredited veterinarian. 
Immediately after the surgical procedure and before the sample removal, a computed 
tomography (CT) scan was performed (Figure S3 in supporting information). The 
sample size for each type of scaffold was n = 6. 
2.9 Histological processing 
The bone segments containing the defect were dissected out and fixed by immersion in 
10% neutral buffered formalin (4% formaldehyde) for 7 days. Bone segments were 
divided into 4 mm-thick slices with an EXAKT 300 CP band-saw, and post-fixed in the 
same fixative for another 4 days. Bone slices were dehydrated by immersion in a graded 
ethanol series and embedded in Technovit 7210 VLC resin, which was light-
polymerized. Polymerized resin blocks were glued to microscope slides and sectioned 
into 0.4 mm-thick sections with a diamond saw. These sections were polished with 
EXAKT 400 GRINDING SYSTEM until obtaining 50 µm-thick histological sections.  
Sections were stained with either von Kossa’s or Masson-Goldner’s Trichrome 
Stainings. For von Kossa’s staining, sections were incubated in 1% silver nitrate 
aqueous solution under ultraviolet light for 20 minutes and rinsed thoroughly for five 
times in bi-distilled water. Unreacted silver was removed by washing with 5% sodium 
thiosulfate aqueous solution, followed by new washes in bi-distilled water. Nuclei were 
counterstained with Nuclear Fast Red. Masson-Goldner’s Trichrome Staining was 
performed as described by Goldschlager [38]. Histomorphometric quantification of 
bone ingrowth and blood vessels density was carried out by a blind reviewer (LSR) 
using the slides obtained from the half height section of the cylindrical scaffolds. For the 




each histological slice and scanning the defect in both vertical and horizontal directions 
and crossing the center. 
2.10 Image acquisition and analysis 
Images were obtained with an Olympus VS120 photo-microscope and analysed with 
ImageJ to calculate defect area and bone area in each section, as well as number of 
blood vessels. Data were plotted and statistically analysed with GraphPad Prism7. 
2.11. Statistics 
In vitro cell culture data were expressed as means ± standard deviations of a 
representative of three experiments carried out in triplicate. Statistical analysis was 
performed using the Statistical Package for the Social Sciences (SPSS) version 19 
software. One-way ANOVA followed by Scheffé post hoc test were used to evaluate 
differences among groups for in vitro results and two-way ANOVA to compare the 
effects of SiHA and VEGF for histological data. In all the statistical evaluations, p ˂ 
0.05 was considered as statistically significant. 
3. Results 
3.1 Characterization of Si-HA coatings on Ti6Al4V-ELI scaffolds 
Figure 1.a shows the XRD patterns of the coatings when the sols are aged for 6, 8 and 
24 hours. The XRD patterns show the variation of the crystalline phases of the Si-HA 
coatings as a function of ageing time. The pattern for the sol aged for 6 hours (HASi6H) 
shows diffraction maxima corresponding to a calcium carbonate (CaCO3) as major 
phase, together with diffraction maxima that can be assigned to an apatite-like phase 
(HA). The XRD pattern for the sol aged for 8 hours (HASi8H) shows that the maxima 




assignable to CaCO3. Finally, the XRD pattern corresponding to ageing times of 24 
hours (HASi24H) only shows the diffraction maxima corresponding to an apatite-like 
phase together with several diffraction maxima assigned to the -Ti phase of the 
substrate. 
Figure 2.b show the FTIR spectra for the SiHA coatings aged for different periods. The 
spectrum of the coating deposited after 6 hours of ageing (HASi6H) shows intense 
adsorption bands corresponding to the vibration of carbonate ions (1407 and 870 cm-1). 
A broad vibration band (medium intensity) corresponding to low crystalline phosphates 
at 1050 cm-1 and a singlet signal at 520 cm-1 characteristics of amorphous phosphate are 
also observed. The coatings deposited after 8 hours of ageing (HASi8H) point out a 
decrease of carbonate content, whereas the absorption bands for phosphates are more 
intense and indicate more crystallinity as can be deduced from the doublet signal 
corresponding to the bending mode of O-P-O bonds in crystalline environments. 
Finally, coatings deposited from sols aged for 24 hours (HASi24H) show the absorption 
bands corresponding to the bending vibration in crystalline phosphates (doublet at 603 
and 567 cm-1), P-O stretching bands (1089, 1054, and 961 cm-1) and the band 
corresponding to the librational mode of hydroxyl groups in hydroxyapatite. Besides, 
the carbonate band at 1400 cm-1 significantly decreases, in agreement with the absence 
of calcite determined by XRD. 
Figure 2c shows the SEM images and the EDX spectra of the coatings aged for different 
times. Sols aged for 6 hours (HASi6H)  led to heterogeneous coatings exhibiting 
nodules. These heterogeneities are not observed in HASi8H coatings; however these 
coatings show cracks, which introduce certain degree of heterogeneity on the surface. 
Finally, sols aged for 24 hours (HASi24H) led to crack-free homogeneous coatings made 




3.2 Determination of VEGF adsorption and cell culture tests 
VEGF adsorption on Ti and Ti@SiHA scaffolds reaches over 90% after 30 minutes in 
both cases (p < 0.005) (Figure 2). At this short time, VEGF adsorption on Ti@SiHA is 
significantly higher than on Ti scaffolds (p < 0.005), demonstrating that SiHA coating 
accelerates VEGF adsorption on these structures. After 24 hours, the adsorbed VEGF 
percentages were the same in both non-coated Ti and Ti@SiHA scaffolds. 
Endothelial cell proliferation is significantly higher on Ti-VEGF and Ti@SiHA-
VEGF scaffolds compared to scaffolds without VEGF (p < 0.005) (Figure 3.a). The best 
proliferation results are obtained with endothelial cells cultured on non-coated scaffolds 
after adsorption of VEGF (Ti-VEGF samples). SEM observations suggest that 
endothelial cells proliferate on all the scaffolds and cover the surface of both coated and 
non-coated scaffolds (Figure 3.b).  
The in vitro response of bone cells to all these structures was evaluated by 
culturing MC3T3 pre-osteoblasts. Figure 4.a shows that the scaffolds coated with SiHA 
(Ti@SiHA and Ti@SiHA-VEGF) exhibit a significant increase of pre-osteoblasts 
proliferation (p < 0.005). The higher pre-osteoblasts proliferation was obtained when 
pre-osteoblasts are cultured on Ti@SiHA-VEGF, although there is not statistical 
significance when compared with Ti@SiHA scaffolds. Regarding non-coated scaffolds, 
a significant increase of pre-osteoblast proliferation (p < 0.05) was observed in Ti-
VEGF respect to Ti.  
SEM studies were also carried out with MC3T3 pre-osteoblasts cultured on 
scaffolds with or without adsorbed VEGF. Pre-osteoblast proliferate on all these 
materials and completely cover the surface of both coated and non-coated scaffolds 
(Figure 4.b). More granularity is observed on SiHA-coated samples compared to non-




3.3 Histological evaluation and histomorphometric quantification of bone ingrowth and 
blood vessels 
Figure 5 shows the histological sections after 12 weeks of implantation in an 
osteoporotic sheep animal model. Empty control defects did not get filled with newly-
formed bone, although some bone growth was observed at the periphery of the defect, 
as part of the natural healing reaction. Similar peripheral growth was found in groups 
implanted with Ti and Ti-VEGF. In these groups, there was also some growth next to 
the titanium bars closer to the periphery. Groups implanted with Ti@SiHA and 
Ti@SiHA-VEGF also presented this type of growth but, interestingly, bone was 
frequently found on the inner struts (black arrows in figure 5.d). In some cases, this 
bone is connected to the peripheral bone (red arrow in figure 5.d). Quantification of 
newly-formed bone revealed the extent of ossification to be significantly higher in 
Ti@SiHA-VEGF as compared to the rest of the groups when considering both, the 
whole defect and the central third of the defect (Figure 6). 
Figure 7 shows histological sections of Ti@SiHA and Ti@SiHA-VEGF 
(Masson-Goldner’s Trichrome Stainings) after 12 weeks of implantation. In the case of 
the scaffolds with VEGF adsorbed, the images evidence thicker trabeculae and a higher 
number of blood vessel. The quantitative study (Figure 8) showed a significantly higher 
number  of vessels in Ti@SiHA-VEGF compared with the same scaffold without VEGF 
(Ti@SiHA). In order to test the uniformity of blood vessels formation, we also 
quantified the number of vessels formed in the peripheral region and central region of  
Ti@SiHA and Ti@SiHA-VEGF scaffolds. No significant differences were found 





Metallic macroporous scaffolds are a promising alternative to the current 
substitutive strategies in the treatment of bone defects. These scaffolds facilitate the 
osteogenesis and new blood vessels formation within their macroporous structure, while 
exhibiting optimal mechanical behavior. Both aspects are mandatory for bone 
regeneration, particularly in osteoporotic bones where the implant integration with the 
hosting bone is seriously affected due to the low bone formation rate in the peri-implant 
region [40]. These implants provide strong scaffolding to the bone with porosities 
higher than 50% in volume. Consequently, it would be highly desirable if they exhibited 
osteogenic capabilities to enhance bone ingrowth within the macroporous structure. 
 In this work we have achieved this aim by coating microporous Ti6Al4V-ELI 
scaffolds with silicon substituted hydroxyapatite and subsequent adsorption of VEGF. 
Previously, different synthesis parameters were strictly controlled to prepare 
homogeneous and stable coatings. Among them, the ageing time of the sol is a 
determining parameter in dip coating processes. Ageing times below 24 hours were not 
enough to obtain crack-free SiHA coatings, resulting in a heterogeneous deposition of 
material composed by calcium carbonate and calcium phosphate as secondary phase. On 
the contrary, ageing periods of 24 hours followed by three dipping-withdrawal cycles 
allow for the complete hydrolysis of phosphate and silicon precursors, so that a unique 
SiHA phase with Ca/P+Si ratio of 1.67 is obtained. SiHA coating so obtained facilitates 
VEGF adsorption on these structures. VEGF is adsorbed very efficiently after 30 min in 
contact with Ti@SiHA scaffolds, although uncoated Ti scaffolds also exhibited high 
and stable non-covalent adsorption capability for this growth factor. After 24 hours both 
Ti-VEGF and Ti@SiHA-VEGF showed the same levels of VEGF adsorption close to 
100%. Concerning the release kinetics of the VEGF from the scaffold, in preliminary 




disks of nanocrystalline and crystalline hydroxyapatites with different Si proportions for 
different times after VEGF adsorption [19]. Very low levels (lower than 2 ng/ml) of 
desorbed VEGF were observed 96 hours after the initial time in all the cases, thus 
indicating the effective immobilization of VEGF. 
Although no differences could be detected by SEM between coated and non-
coated scaffolds, VEGF seems to improve the endothelial cell adhesion and 
proliferation on the surface of all these structures. This fact is observed in both series 
containing VEGF, pointing out the relevance of this growth factor as an important 
mediator of endothelial cell proliferation and survival [39].  Besides, endothelial cells 
proliferation is significantly higher in Ti-VEGF compared with Ti@SiHA-VEGF. This 
result would point out that SiHA coating could decrease the stimulatory proliferation 
effect elicited by VEGF in EC2 cells. 
The scaffolds coated with SiHA (Ti@SiHA and Ti@SiHA-VEGF) exhibit a 
significant increase of pre-osteoblast proliferation. These results highlight the relevance 
of this coating for bone cells and agree with the specific characteristics of silicon 
substituted hydroxyapatite. It is well known that silicon substitution of the 
hydroxyapatite potentiates pre-osteoblast proliferation and maturation by different 
established biochemical mechanisms [41]. Besides, a significant increase of pre-
osteoblast proliferation (p < 0.05) is observed in Ti-VEGF respect to Ti scaffolds, 
suggesting the effect of VEGF adsorption on Ti6Al4V scaffolds is also remarkable on 
pre-osteoblasts. On Ti@SiHA scaffolds, the VEGF effect is not significant probably 
due to the beneficial effect of the coating, which masks the action of this growth factor. 
All these in vitro studies demonstrate that Ti-VEGF scaffolds improve the 
proliferation of endothelial cells while pre-osteoblasts prefer to grow on Ti@SiHA-




endothelium and bone tissue, respectively. On the other hand, the SEM images of 
endothelial cells and MC3T3 pre-osteoblasts (Figures 3 and 4, respectively) cultured on 
the different scaffolds with or without adsorbed VEGF, evidence that these two cell 
types proliferate on all the scaffolds and cover their surface forming a perfect 
monolayer which makes difficult to distinguish the cells on the surface. It is important 
to take into account that the formation of an endothelial cell monolayer plays a key role 
in the development of tissue engineered vascular grafts and facilitate the organ 
functions.  
In order to evaluate the osteogenic capability of  the scaffolds in conditions 
simulating osteoporosis in humans, we have implanted the four series in an osteoporotic 
sheep model. This ovine model, combining ovariectomy with a low calcium diet and 
corticosteroid administration, has been previously described in the literature [42,43]. 
One limitation of our study was that we could not achieve a dose of calcium of 0.15-
0.25% as described by other authors [43,44] due to technical limitations, although it was 
lower than that found in the normal diet. Nevertheless, an osteoporotic model has been 
described as well with a combination of ovariectomy and glucocorticoids administration 
alone determining that it constitutes a relevant preclinical model for orthopaedic implant 
and biomaterial research [45], being the best effects for osteoporosis induction obtained 
using ovariectomised sheep with methylprednisolone injections [46]. Even more, 
Stadelmann et al. [47] described an osteoporotic model with ovariectomized sheep after 
6 months with no restriction in calcium and no corticosteroids administration. The 
authors reported a reduction of 30% in bone volume fraction, 11% in trabecular 
thickness and 19% in trabecular number, as well as a 14% increase in trabecular 
separation, although the structural model index was not significantly affected.  




et al. [42] for osteoporotic sheep models in order to minimize the side effects produced 
by long-term treatments but maintaining the osteopenia conditions. Additionally, a 
minimally invasive approach was used for the ovariectomy to decrease discomfort and 
pain in the animals. 
 After 12 weeks in vivo, clear differences were observed between samples. In the 
control defect, no bone formation (figure 5.a) or new bone formation restricted to 
peripheral regions was observed (see supporting information, Figure S4), whereas 
uncoated Ti scaffolds showed moderate bone ingrowth from peripheral region towards 
the inner parts. The adsorption of VEGF did not modify the bone in-growth pattern, i.e. 
bone regeneration also occurs from peripheral region. However, the presence of VEGF 
seems to stimulate the formation of thicker trabeculae in Ti-VEGF compared to Ti 
scaffolds.  
 Coating Ti6Al4V scaffolds with SiHA did not improve the amount of newly 
formed bone respect to Ti. In the absence of VEGF, trabeculae formed on Ti@SiHA are 
thin and poorly developed, similarly to those observed for naked Ti. However, the 
scaffolds with SiHA coatings show some bone formation in the inner struts of 
Ti@SiHA scaffolds in addition to that originated from the peripheral bone. This bone 
growth might start in the inner struts or there might be out-of-plane growth from the 
periphery. This fact would agree with the osteoinductive properties of silicon-
substituted hydroxyapatites previously pointed by Patel et al [48,49], although more 
work, like the quantification of bone growth patterns in 3D, would be needed to identify 
if bone formation does truly start at the inner struts. 
 Despite of the positive outcomes associated to the presence of SiHA coatings 
and VEGF separately (Ti@SiHA and Ti-VEGF scaffolds), only Ti@SiHA-VEGF 




than either Ti@SiHA, Ti-VEGF or Ti scaffolds (19.6 ± 5.6%, 26.7 ± 12.6% and 17.8 ± 
13.2 % bone volume, respectively). In addition, the newly formed bone exhibited 
thicker trabeculae with a more developed vascular system.  
These results must be understood in terms of the multiple effects that SiHA 
coating and VEGF can exert on different cell types, as well as the role of each one plays 
in osteogenesis and angiogenesis. Coating Ti6Al4V-ELI scaffolds with SiHA and 
subsequent adsorption of VEGF suggest an interplay between the bioactive coating and 
the grow factor for bone regeneration. As we could observe in our in vitro cell culture 
tests, SiHA coating stimulates pre-osteoblast proliferation on the scaffolds surface. In 
vivo studies carried out with rabbits demonstrated the capability of silicon substituted 
hydroxyapatites to promote bone ingrowth and repair, characterized by a dense 
trabecular morphology [50]. These biological outcomes are sensitive to the silicon 
content, as it was also observed in an ovine model where the rate and quality of bone 
apposition was enhanced with Si substitution [48]. This enhanced osteogenic 
performance is explained in terms of the excellent osteoconductive properties provided 
by the hydroxyapatite phase, together with the significant up-regulation of osteoblast 
proliferation and gene expression mediated by soluble silica species [51,52]. Besides, 
our in vitro cell culture tests demonstrate that VEGF adsorbed on Ti and Ti@SiHA 
scaffolds stimulates the proliferation of endothelial cells. The excellent osteogenic 
response in this sheep model for osteoporosis could be explained in terms of a previous 
stimulated angiogenesis within the defect and subsequent recruitment and supporting of 
osteoprogenitor cells. Although the VEGF dose used in this study was chosen in 
agreement with recent studies by others [53], this response would be reinforced by the 
osteoinductive capability of SiHA coated scaffolds, which are able to stimulate new 






Macroporous Ti6Al4V scaffolds coated with silicon-substituted hydroxyapatite and 
decorated with VEGF have been prepared and evaluated as bone graft for bone 
regeneration purposes. 
In vitro cell culture tests evidence that those scaffolds with adsorbed VEGF stimulate 
proliferation of endothelial cells on the scaffolds surface, whereas those scaffolds coated 
with SiHA stimulate proliferation of pre-osteoblasts. 
In vivo studies on a sheep model for osteoporosis evidence that neither SiHA coating 
nor VEGF adsorption enhance osteogenesis separately. However, the adsorption of 
VEGF on SiHA coated scaffolds exhibits a synergistic effect resulting in more 
ossification, larger trabeculae and higher angiogenesis degree.  
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Figure 1. XRD patterns (A), FTIR spectra (B) and SEM images (C) of the coatings 
deposited on Ti6Al4V scaffolds after 6, 8 and 24 hours of aging. The insets show the 
EDX spectra obtained from the scaffolds surface during SEM observations 
Figure 2. Indirect evaluation of VEGF adsorption on Ti (white) and Ti@SiHA (grey) 
scaffolds. VEGF union percentage at various times was analyzed by measuring free 
VEGF in the supernatants by ELISA. *Comparison between each material at various 
times. Comparison between coated and non-coated scaffolds. Statistical significance: 
*** p < 0.005;  p < 0.005. 
Figure 3. (a) Proliferation of EC2 endothelial cells cultured on Ti and Ti@SiHA 
scaffolds without or with adsorbed VEGF. Cell proliferation was analyzed by 
measuring absorbance at 450 nm after CCK-8 protocol. *Comparison between each 
material without or with VEGF. Comparison between coated and non-coated 
scaffolds. Statistical significance: *** p < 0.005;  p < 0.05. SEM studies of EC2 
endothelial cells cultured on Ti (b), Ti-VEGF (c), Ti@SiHA (d) and Ti@SiHA-VEGF 
scaffolds (e)  
Figure 4. (a) Proliferation of MC3T3 pre-osteoblasts cultured on Ti and Ti@SiHA 
scaffolds without or with adsorbed VEGF. Cell proliferation was analyzed by 
measuring absorbance at 450 nm after CCK-8 protocol. *Comparison between each 
material without or with VEGF. Comparison between coated and non-coated 
scaffolds. Statistical significance: * p < 0.05;   p < 0.005. SEM studies of MC3T3 





Figure 5. Optical micrographs from the histological sections after 12 weeks (von 
Kossa’s staining): (a) control defect, (b) Ti scaffold, (c) Ti-VEGF scaffold, (d) 
Ti@SiHA scaffold. The inset is a magnification of an inner strut with new bone grown 
on it. (e) Ti@SiHA-VEGF. Arrows indicate bone growth non-derived from the border 
of the defect. 
Figure 6.  Defect area covered by new bone. (a)  new bone in the whole defect and (b)  
new bone in the central third of the defect. Statistical significance: * p < 0.05 
Figure 7. Optical micrographs from the histological sections after 12 weeks (Masson-
Goldner’s Trichrome Stainings) obtained from the peripheral regions of (a) Ti@SiHA 
and (b) Ti@SiHA-VEGF scaffolds. Arrows point to blood vessels 
Figure 8. Quantitative evaluation of angiogenesis in Ti@SiHA and Ti@SiHA-VEGF 
scaffolds in the central and peripheral regions of the scaffolds. Statistical significance: * 
p < 0.05. 
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